SEC Filing Summary
Filing identity: The supplied filing is Gold Swap Inc.’s Form 10-Q for the quarter ended September 30, 2011. It does not identify Silo Pharma, Inc.; verify that this is the intended filing before relying on this summary.
Business context and reporting period
Gold Swap describes itself as a development-stage company planning to buy unwanted precious-metal items from consumers, arrange refining and resale, and earn a spread. It reported no revenue from inception on July 13, 2010 through September 30, 2011 and said it had not yet clearly determined how it would operate its business. The interim financial statements are unaudited.
Financial results and position
| Metric | Three months ended September 30, 2011 | Nine months ended September 30, 2011 | At September 30, 2011 |
|---|---|---|---|
| Revenue | None | None | Not applicable |
| General and administrative expense | $17,719 | $43,470 | Not applicable |
| Net loss | $17,719 | $43,470 | Accumulated development-stage deficit: $1,121,975 |
| Cash and total assets | Not provided as period flows | Operating cash use: $43,470 | $4,585 |
| Total liabilities and debt | No liabilities or debt are reported on the balance sheet. | ||
| Stockholders’ equity | $4,585 |
Cash was $47,480 at December 31, 2010, a decrease of $42,895 during the first nine months of 2011. Financing cash inflow was $575. Gross margin and operating margin are not meaningful because the company had no revenue.
Changes versus prior periods
Third-quarter 2011 net loss of $17,719 compared with $450 for the three-month period shown for 2010; management attributed the increase mainly to professional fees. Nine-month 2011 general and administrative expense was $43,470. The cumulative loss since inception was principally driven by $1,075,000 of compensation expense recorded for 21.5 million shares issued to officers and directors in July 2010. Cash declined from $47,480 at year-end 2010 to $4,585 at September 30, 2011.
Outlook, liquidity, and risks
- The company planned over the next 12 months to locate refinery partners, solicit consumer sales, facilitate shipment of items for refining, and seek profit from the spread between scrap and spot prices. It had no day-to-day operations beyond attempting to meet its stated timeline.
- Management said existing funds were insufficient to execute its proposed operating and marketing plans and that additional capital would be needed. It reported no loan, credit-line, or other financing arrangements in place.
- Officers and directors had orally indicated they would lend funds or cover operating expenses if needed, but none was legally or contractually obligated to do so; the filing gave no committed funding amount. Failure to raise funds could materially impair the company’s ability to continue.
- The filing raises substantial going-concern concerns: the company had no revenue, limited cash, and relied on commencing operations and potential related-party debt or equity. No assurance of financing or successful launch was provided.
- The company reported no off-balance-sheet arrangements, pending legal proceedings, or capital-expenditure commitments. It stated that disclosure controls were effective and that there had been no material change in internal control over financial reporting.
Important facts to verify
- Confirm the issuer: the filing names Gold Swap Inc., while the request identifies Silo Pharma, Inc.
- Reconcile the MD&A’s statement that nine-month net loss was $17,719 with the financial statements, which report $43,470. The MD&A also describes nine-month operating cash use as $43,470; the cash-flow statement reports that amount.
- Verify the status and terms of the officers’ and directors’ oral funding assurances, which are not binding commitments.
- Assess whether the company obtained financing, established refinery arrangements, or began revenue-generating operations after the reporting date; this filing gives no subsequent outcome.
- The filing says it was not required to provide the specified risk-factor disclosures as a smaller reporting company; the absence of a detailed risk-factor section is not evidence that risks were absent.